Business Wire

Canva Expands Developer Platform As App Uses Surpass 1 Billion

25.9.2024 20:30:00 EEST | Business Wire | Press release

Share

Canva, the world’s only all-in-one visual communication platform, today unveiled updates for its growing Canva Developers community, as part of its vision to build the world’s most pluggable design platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925330023/en/

Canva Extend 2024 (Photo: Business Wire)

At the company’s second annual Canva Extend conference in San Francisco, Canva introduced several new APIs, monetization through a premium apps program and added tools to help builders scale their businesses.

In one year, Canva’s developer community has expanded to include members from 122 countries, contributing to a marketplace of 300 apps and counting. These apps have been used 1 billion times since the start of the Canva Developer Program in June 2023. Building on the Canva platform gives developers a simple way to put their app in the hands of Canva’s 190 million monthly active users, who in turn benefit from access to new technology to achieve their goals.

"Our vision is to create the most interoperable work platform through apps and integrations, while offering a rewarding experience for the developers who build them,” said Anwar Haneef, GM and Head of Ecosystem at Canva. “In partnership with developers from around the world, we’ve introduced hundreds of AI and design capabilities and are scaling Canva faster than ever. We’re incredibly excited to continue growing together in the years ahead.”

Canva adds value and growth opportunities for app developers

Users in an infinite range of professions and organizations are already embracing apps on Canva to speed up content creation, enhance their editing and find new inspiration.

Today’s updates expand what can be built on Canva, and make apps easier for users to discover:

  • Monetization - With the Premium Apps Program, eligible developers can include premium features in their apps and get paid for those features based on engagement.
  • Translation services - Canva will translate app content to help developers engage its global user base, for free.
  • Easier app discovery- Apps will now be shown alongside Canva’s own editing tools on the platform’s Text tab, Elements tab, Photo Editor, inside Canva Docs and more. This makes it easier for users to find apps most relevant to their work.
  • New app APIs- Canva is expanding its Canva Apps SDK with a new suite of capabilities:
    • Content Query API - enables apps to read and update text, unlocking possibilities for translation apps, document AI assistants, writing assistants and more.
    • Design Editing API (beta) -makes design and layout automation easy, such as for an app that adds or modifies elements in a plain design based on prompts.
    • Tables API - lets apps add tables with content to designs.
    • Authentication API - simplifies authentication for apps, making it easier to implement industry-standard OAuth protocol.

In addition to APIs and monetization opportunities, Canva Developers have access to resources that range from app design to go-to-market assistance.

“With so many marketers using Canva to create organic and paid media assets for Meta, we wanted to build an app that makes it seamless for them to apply Meta’s creative best practices. We worked hand-in-hand with Canva on design, development, and go-to-market efforts for the Meta Design Check app, which truly simplifies the creative process for our users,” said Cecilia LV, Strategic Partnerships Lead at Meta.

A growing AI ecosystem

Following Canva’s acquisition of Leonardo.Ai in July, Canva also announced that developers can apply for access to Leonardo’s APIs, and receive initial credits to build their app.

Apps and integrations have become core to Canva’s AI strategy, and more than half of what’s found in the Canva Apps Marketplace is AI-powered. AI developers are finding a passionate audience on Canva. For example, during their first month on Canva, DeepReel grew new user sign ups by more than 10x, and Krikey 3D AI Animation saw a 23x increase in site traffic the day after launching their app on Canva.

Connect APIs and new Salesforce integrations show the power of a pluggable workflow

Since their launch in June of this year, organizations have been leveraging Canva’s Connect APIs to embed Canva into their workflows or products, with more than 300 Connect API integrations in active development.

Last week, Canva introduced Canva for Salesforce, a set of integrations powered by Connect APIs that turn custom datasets into assets that leave a lasting impression.

Sales teams can populate on-brand Canva templates with opportunity or account information from Salesforce in a single click, and also generate charts using data input from Salesforce. By automating the creation of custom presentations and pitch assets, sales teams can better focus on strategy and closing business.

Salesforce is one of several work platforms building on Canva, joining apps from Amazon Ads, Meta and Google Ads. Connect APIs are also bridging Canva with cloud integration platforms (iPaaS) like Workato, Zapier and Make.

Developer initiatives support Canva’s enterprise growth

Today’s announcements follow the launch of Canva Enterprise in May 2024, which gives organizations more control over how their teams use Canva. The addition of new APIs and developer resources makes it easier for teams to access essential data and use Canva alongside other essential workplace tools. Canva is now used in 95% of Fortune 500 companies, and has surpassed 190 million users and $2.3B in revenue.

About Canva

Launched in 2013, Canva is a free online visual communications and collaboration platform with a mission to empower everyone in the world to design. Featuring a simple drag-and-drop user interface and a vast range of templates ranging from presentations, documents, websites, social media graphics, posters, apparel to videos, plus a huge library of fonts, stock photography, illustrations, video footage, and audio clips, anyone can take an idea and create something beautiful.

Salesforce and others are among the trademarks of Salesforce, inc.

Downloadable Assets

Here

View source version on businesswire.com: https://www.businesswire.com/news/home/20240925330023/en/

Contacts

oliviajohnson@canva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye